https://www.prognyx.com/blog/verastem-s-vs-7375-hits-50-response-in-second-line-pancreatic-cancer-phase-3-nexPrognyxen2026-10-16Verastem's VS-7375 hits 50% response in second-line pancreatic cancer, Phase 3 next https://www.prognyx.com/blog/fda-expands-immunitybio-s-anktiva-label-to-papillary-only-nmibcPrognyxen2026-10-15FDA expands ImmunityBio's Anktiva label to papillary-only NMIBC